Figure 1.

(A) Treatment of AT-EAN with different dosages of rhP2. Lewis rats were injected with 8 × 10⁶, activated, P2-specific T line cells. On days 1–7, one group received 500 μg of rhP2 i.v. twice daily or 100 μg of rhP2 once daily, and control animals were treated with 500 μg of ovalbumin i.v. twice daily. (B) Treatment of ongoing AT-EAN with rhP2. Rats were injected i.v. with 8 × 10⁶ T cell blasts. Three days later, animals were divided into four groups and received, for 4 days, twice daily, either 500 μg of rhP2, 100 μg of rhP2, 500 μg of ovalbumin, or 100 μg of rhP0. Differences between the ovalbumin or rhP0 groups and treatment with 100 or 500 μg of rhP2 were significant at P < 0.05. OVA, ovalbumin.